Harvard Bioscience CEO’s Share Buy Signals Confidence in Proteomics & ADMET Growth Potential
Harvard Bioscience CEO’s $5.01 share purchase post‑reverse split signals confidence in its proteomics‑ADMET platform; insiders back a strategic play for future growth, but market volatility and tight 52‑week range urge careful monitoring.
4 minutes to read